15 Best Growth Stocks to Invest in for the Next 5 Years

Page 11 of 13

3. Avalo Therapeutics, Inc. (NASDAQ:AVTX)

Upside potential as of June 24, 2025: 511.98%

On Monday, the management of Avalo Therapeutics, Inc. (NASDAQ:AVTX) revealed its participation in the HCW Annual Inflammation & Immunology Virtual Conference, scheduled for June 30, 2025, and BTIG Virtual Biotechnology Conference 2025, planned for July 29–30, 2025.

Earlier on Wednesday, Avalo Therapeutics, Inc. (NASDAQ:AVTX) appointed Rita Jain, M.D., to its Board of Directors. Dr Jain, who previously served as Executive Vice President and Chief Medical Officer at ChemoCentryx, joins the board at the company’s crucial time and plans to advance the Phase 2 LOTUS trial in HS, with results expected in mid-2026.

H.C. Wainwright analysts have upgraded Avalo Therapeutics, Inc. (NASDAQ:AVTX) to Buy from Neutral, while setting the 12-month price target to $15.00, implying an upside of over 200%. The leading candidate, AVTX-009, is what the analysts believe will lead the future of the company. The firm highlights that the mechanism represents an optimal strategy, stating that the competitor data reinforces the effectiveness of this risk-mitigated approach in treating the condition.

Avalo Therapeutics, Inc. (NASDAQ:AVTX), incorporated in 2001, operates as a clinical-stage biotechnology company that develops treatments for immune dysregulation in the United States. The core offering of this Maryland-based company is AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß.

Page 11 of 13